AbbVie announced positive topline results from level UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT, per its labeled dose) in adults and adolescents (12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the level upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index (EASI 90) and a worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibit potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.2 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

Clinical trials of RINVOQ are ongoing in alopecia areata, ankylosing spondylitis, atopic dermatitis, axial spondyloarthritis, Crohn's disease, giant cell arteritis, hidradenitis suppurativa, psoriatic arthritis, systemic lupus erythematosus (SLE), Takayasu arteritis, ulcerative colitis and vitiligo. RINVOQ is a prescription medicine used to treat: Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. Adults with active psoriatic arthritis (PsA) when 1 or more medicines call TNF blockers have been used, and was not work well or could not been tolerated.

Adults with active psoratic arthritis (PsA) When 1 or more medicines called TNF blockers have been used and did not work well or would not be tolerated. Adults with Active psoriatic arthritis (Ps A) when 1 or more medicines calls TNF blockers have been used. Adults with active psoriatics arthritis (PsA) when1 or more medicines called TNF inhibitors have been used, and did no work well or could not be toler.

Adults with active psoriatically arthritis (PsA) when one or more medicines called TNF blocking have been used, and did Not work well or could not be permitted.